We are live on ! Find out more
FM

Frazier Management Portfolio holdings

AUM $1.12M
1-Year Est. Return 151.58%
This Fund
S&P 500
This Quarter Est. Return
+5.01%
1 Year Est. Return
+151.58%
3 Year Est. Return
+408.4%
5 Year Est. Return
+1,802.6%
10 Year Est. Return
–
AUM
$1.11B
AUM Growth
-$24.9M
Cap. Flow
+$22M
Cap. Flow %
1.98%
Top 10 Hldgs %
85.85%
Holding
31
New
5
Increased
1
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
FRLN
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
+$9.19M
2
RGNX icon
Regenxbio
RGNX
+$5.68M
3
BLU
BELLUS Health Inc.
BLU
+$3.68M
4
NERV icon
Minerva Neurosciences
NERV
+$1.86M
5
CRDF icon
Cardiff Oncology
CRDF
+$1.72M

Top Sells

Rank Stock Value
1
ETTX
Entasis Therapeutics Holdings Inc.
ETTX
+$428K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARQT icon
1
Arcutis Biotherapeutics
ARQT
$3.13B
$309M 27.73%
10,542,790
– –
PHAT icon
2
Phathom Pharmaceuticals
PHAT
$723M
$214M 19.18%
5,827,415
– –
PCVX icon
3
Vaxcyte
PCVX
$9.1B
$114M 10.24%
2,309,554
– –
MIRM icon
4
Mirum Pharmaceuticals
MIRM
$6.08B
$68.7M 6.17%
3,566,912
– –
PASG icon
5
Passage Bio
PASG
$13.9M
$65.7M 5.9%
250,461
– –
IOVA icon
6
Iovance Biotherapeutics
IOVA
$3.74B
$43.2M 3.88%
1,312,999
– –
TRIL
7
DELISTED
Trillium Therapeutics Inc.
TRIL
$39.6M 3.55%
2,788,443
+33,443
+1% +$333K
KRYS icon
8
Krystal Biotech
KRYS
$10.6B
$38.5M 3.46%
895,000
– –
ANAB icon
9
AnaptysBio
ANAB
$1.7B
$34.2M 3.07%
2,316,447
– –
TBIO
10
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$29.7M 2.67%
2,182,789
– –
ALPN
11
DELISTED
Alpine Immune Sciences Inc
ALPN
$22.6M 2.03%
2,571,450
– –
COLL icon
12
Collegium Pharmaceutical
COLL
$820M
$19.6M 1.76%
943,666
– –
SNDX icon
13
Syndax Pharmaceuticals
SNDX
$1.8B
$19.5M 1.75%
1,320,045
– –
ADVM
14
DELISTED
Adverum Biotechnologies
ADVM
$14.8M 1.33%
143,703
– –
ISEE
15
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$13.3M 1.2%
2,364,500
– –
RCKT icon
16
Rocket Pharmaceuticals
RCKT
$397M
$12.1M 1.08%
528,000
– –
APTX
17
DELISTED
Aptinyx Inc. Common Stock
APTX
$10.8M 0.97%
3,190,079
– –
FRLN
18
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
$8.59M 0.77%
+36,667
New +$9.19M
GRTS
19
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$5.46M 0.49%
2,061,758
– –
ALNA
20
DELISTED
Allena Pharmaceuticals
ALNA
$4.93M 0.44%
3,330,373
– –
RGNX icon
21
Regenxbio
RGNX
$619M
$4.79M 0.43%
+174,200
New +$5.68M
CDTX
22
DELISTED
Cidara Therapeutics
CDTX
$3.74M 0.34%
65,613
– –
CRDF icon
23
Cardiff Oncology
CRDF
$76.7M
$3.69M 0.33%
+260,000
New +$1.72M
BLU
24
DELISTED
BELLUS Health Inc.
BLU
$2.96M 0.27%
+1,296,743
New +$3.68M
NBRV
25
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$2.27M 0.2%
17,026
– –
1
2

Similar funds

ACMV
August Capital Management VI Palo Alto, California $1.39M AUM
FRCMI
First Round Capital Management III Philadelphia, Pennsylvania $418K AUM
DB
DCVC Bio Palo Alto, California $313K AUM
NAM
Newfleet Asset Management Hartford, Connecticut $2.05M AUM 27.28% 1-Year Est. Return
AP
Atlas Principals Charlotte, North Carolina $2.19M AUM 56.71% 1-Year Est. Return
ID
Inspire Developers Forest Hills, New York $4.07M AUM
CI
CMT Investments Chicago, Illinois $5M AUM 15.27% 1-Year Est. Return
DIF
Discovery Investment Fund Singapore $6.98M AUM

Frazier Management's Q3 2020 Portfolio in Review

As of Q3 2020, Frazier Management held 31 positions worth $1.11B, down 2.2% from $1.14B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Frazier Management's Q3 2020 filing shows 5 new, 1 increased and 1 reduced positions. Its largest new stake was Freeline Therapeutics Holdings plc American Depositary Shares: 36,667 shares worth $8.59M. The largest sale was Entasis Therapeutics Holdings Inc., an estimated $428K.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Frazier Management's largest Q3 2020 buy was Freeline Therapeutics Holdings plc American Depositary Shares: 36,667 shares worth $8.59M.
  • Frazier Management added most to Trillium Therapeutics Inc. in Q3 2020, an estimated $333K increase.
  • Frazier Management's biggest Q3 2020 reduction was Entasis Therapeutics Holdings Inc., cutting an estimated $428K.
  • Frazier Management's ten largest holdings make up 86% of its $1.11B portfolio in Q3 2020.
  • Frazier Management opened 5 new positions and closed 0 in Q3 2020.
  • Frazier Management's portfolio value fell 2.2% quarter-over-quarter to $1.11B.

Based on Frazier Management's 13F filing for Q3 2020, filed 12 Nov 2020.